SPRO

This company operates in the biotech sector, focusing on developing new antibiotics to combat drug-resistant bacteria. It competes with larger pharmaceutical firms by targeting niche infections where treatment options are limited. The industry faces challenges like high research costs and regulatory hurdles, but demand is growing due to increasing antibiotic resistance.